Skip to main content
All lobbying filings

MERCK & CO, INC.

Lobbying for MERCK & CO INC

 Filing 4th Quarter - Report
4th Quarter (Oct 1 - Dec 31) 2025 · New Jersey · House · Senate · $1,930,000.00 expenses · posted Jan 20, 2026

Official filing document

 Bills named in this filing 2
 Lobbying activity 4
Health Issues

S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; FY-2026 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Vaccine Policy; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing.

Medicare/Medicaid

Issues relating to, One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; Medicare; Medicare Part B and D drug pricing issues; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug pricing; Medicaid drug rebate program Cost and value of medicines: Drug pricing and reimbursement issues; FY-2026 Budget and Appropriations Legislation; Medicaid drug rebate program (MDRP).

Taxation/Internal Revenue Code

Issues relating to, Tax reform and tax policy, generally; Inflation Reduction Act (P.L. 117-169), provisions relating to budget reconciliation and taxes.

Animals

Issues relating to, Agriculture; Animal Health Technology; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; Rural development; Administration and related agencies appropriations bill, FY-26.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem